Form Type:  SC 13G/A
Filing Date:  6/9/2020 
CIK:  0001280600 
Address:  128 SIDNEY STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  617-649-9200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-7.34 (-6.90%)  
Trade Time: 
Aug 07  
Market Cap: 
Trade XLRN now with 

© 2020  
Description of Business
We are a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have generated several innovative therapeutic candidates, all of which encompass novel potential first-in-class mechanisms of action. If successful, these candidates could have the potential to significantly improve clinical outcomes for patients across these areas of high, unmet need. We have focused and prioritized our research and development activities within three key therapeutic areas: hematology, pulmonary and neuromuscular. Hematology In November 2019, the U.S.
Register and access this filing in: